MATTHEW M. WALSH - 31 Mar 2022 Form 4 Insider Report for Organon & Co. (OGN)

Role
Chief Financial Officer
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Matthew M. Walsh
Issuer symbol
OGN
Transactions as of
31 Mar 2022
Transactions value $
$0
Form type
4
Filing time
04 Apr 2022, 18:11:16 UTC
Previous filing
19 Aug 2021
Next filing
05 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Award $0 +23.3K $0.00 23.3K 31 Mar 2022 Common Stock 23.3K Direct F1, F2
transaction OGN Stock Option (right to buy) Award $0 +71.6K $0.00 71.6K 31 Mar 2022 Common Stock 71.6K $34.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU.
F2 These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025.
F3 The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025.